Use and safety of erythromycin and metoclopramide in hospitalized infants

Journal of Pediatric Gastroenterology and Nutrition

Volumn 61, Issue 3, 2015, Pages 334-339

  Ericson, Jessica E ^a   Arnold, Christopher ^b   Cheeseman, Jomani ^a   Cho, Jordan ^a   Kaneko, Sarah ^a   Wilson, Ele'na ^a   Clark, Reese H ^c   Benjamin, Daniel K ^a   Chu, Vivian ^b   Smith, P Brian ^a   Hornik, Christoph P ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Pediatrix Obstetrix Center for Research and Education   (United States)

Author keywords

Adverse events; Erythromycin; Metoclopramide; Neonatal intensive care unit

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOPHYLLINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN GLUCURONIDE; CAFFEINE CITRATE; CHLOROTHIAZIDE; CREATININE; ERYTHROMYCIN; FLUCONAZOLE; FUROSEMIDE; GAMMA GLUTAMYLTRANSFERASE; GENTAMICIN; LEVOTHYROXINE; METOCLOPRAMIDE; PHENOBARBITAL; RANITIDINE; RECOMBINANT ERYTHROPOIETIN; RETINOL; SPIRONOLACTONE; VANCOMYCIN; GASTROINTESTINAL AGENT;

ABNORMAL LABORATORY RESULT; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; ELECTROLYTE BLOOD LEVEL; FEEDING DIFFICULTY; FEMALE; GASTROESOPHAGEAL REFLUX; HOSPITAL DISCHARGE; HOSPITALIZED INFANT; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERNATREMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFANT; LEUKOCYTOSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEONATAL INTENSIVE CARE UNIT; NEUTROPENIA; PRIORITY JOURNAL; PYLORUS STENOSIS; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; ADVERSE EFFECTS; CHEMICALLY INDUCED; ENTERIC FEEDING; INCIDENCE; INFANT, PREMATURE, DISEASES; NEWBORN; PREMATURITY; PYLORIC STENOSIS, HYPERTROPHIC; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ENTERAL NUTRITION; ERYTHROMYCIN; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; HYPERKALEMIA; INCIDENCE; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS, NEONATAL; MALE; METOCLOPRAMIDE; PYLORIC STENOSIS, HYPERTROPHIC; RETROSPECTIVE STUDIES;

EID: 84988835976     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000792     Document Type: Article

References (41)

1. Weber FH Jr, Richards RD, McCallum RW. Erythromycin: A motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993;88:485-90.
2. EryPed (erythromycin ethylsuccinate for oral suspension) [package insert]. Atlanta, GA: Arbor Pharmaceuticals.
3. Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 2001;139:380-4.
4. Cooper WO, Griffin MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002;156:647-50.
5. Katapadi K, Kostandy G, Katapadi M, et al. A review of erythromycininduced malignant tachyarrhythmia-Torsade de pointes. A case report. Angiology 1997;48:821-6.
6. Benoit A, Bodiou C, Villain E, et al. QT prolongation and circulatory arrest after an injection of erythromycin in a newborn infant [Article in French]. Arch Fr Pediatr 1991;48:39-41.
7. Hyman PE, Abrams C, Dubois A. Effect of metoclopramide and bethanechol on gastric emptying in infants. Pediatr Res 1985;19: 1029-32.
8. Machida HM, Forbes DA, Gall DG, et al. Metoclopramide in gastroesophageal reflux of infancy. J Pediatr 1988;112:483-7.
9. Hyams JS, Leichtner AM, Zamett LO, et al. Effect of metoclopramide on prolonged intraesophageal pH testing in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1986;5:716-20.
10. De Loore, I, Van Ravensteyn, H, Ameryckx L. Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide. Postgrad Med J 1979;55 (suppl 1):40-2.
11. Tolia V, Calhoun J, Kuhns L, et al. Randomized, prospective doubleblind trial of metoclopramide and placebo for gastroesophageal reflux in infants. J Pediatr 1989;115:141-5.
12. Reglan (metoclopramide hydrochloride) injection, solution. Deerfield, IL: Baxter Healthcare Corporation; 2010.
13. Ehrenpreis ED, Deepak P, Sifuentes H, et al. The metoclopramide black box warning for tardive dyskinesia: Effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Am J Gastroenterol 2013;108:866-72.
14. Hsieh EM, Hornik CP, Clark RH, et al. Medication use in the neonatal intensive care unit. Am J Perinatol 2014;31:811-22.
15. Spitzer AR, Ellsbury DL, Handler D, et al. The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system-Tools for "meaningful use" in continuous quality improvement. Clin Perinatol 2010;37:49-70.
16. Aly H, Abdel-Hady H, Khashaba M, et al. Erythromycin and feeding intolerance in premature infants: A randomized trial. J Perinatol 2007; 27:39-43.
17. Gokmen T, Oguz SS, Bozdag S, et al. A controlled trial of erythromycin and UDCA in premature infants during parenteral nutrition in minimizing feeding intolerance and liver function abnormalities. J Perinatol 2012;32:123-8.
18. Ng YY, Su PH, Chen JY, et al. Efficacy of intermediate-dose oral erythromycin on very low birth weight infants with feeding intolerance. Pediatr Neonatol 2012;53:34-40.
19. Ng PC, Lee CH, Wong SP, et al. High-dose oral erythromycin decreased the incidence of parenteral nutrition-Associated cholestasis in preterm infants. Gastroenterology 2007;132:1726-39.
20. Oei J, Lui K. A placebo-controlled trial of low-dose erythromycin to promote feed tolerance in preterm infants. Acta Paediatr 2001;90: 904-8.
21. Patole SK, Almonte R, Kadalraja R, et al. Can prophylactic oral erythromycin reduce time to full enteral feeds in preterm neonates? Int J Clin Pract 2000;54:504-8.
22. Mansi Y, Abdelaziz N, Ezzeldin Z, et al. Randomized controlled trial of a high dose of oral erythromycin for the treatment of feeding intolerance in preterm infants. Neonatology 2011;100:290-4.
23. Nuntnarumit P, Kiatchoosakun P, Tantiprapa W, et al. Efficacy of oral erythromycin for treatment of feeding intolerance in preterm infants. J Pediatr 2006;148:600-5.
24. Mohammadizadeh M, Ghazinour M, Iranpour R. Efficacy of prophylactic oral erythromycin to improve enteral feeding tolerance in preterm infants: A randomised controlled study. Singapore Med J 2010;51: 952-6.
25. Sankaran K, Yeboah E, Bingham WT, et al. Use of metoclopramide in preterm infants. Dev Pharmacol Ther 1982;5:114-9.
26. Madani A, Pourarian S, Zarkesh M. The efficacy of oral erythromycin in enhancement of milk tolerance in premature infants: A randomized clinical trial. Iran J Medical Sci 2004;29:1-4.
27. Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord 2005;20:86-9.
28. Batts KF, Munter DW. Metoclopramide toxicity in an infant. Pediatr Emerg Care 1998;14:39-41.
29. Eras Z, Oguz SS, Dilmen U. Is metoclopramide safe for the premature infant? Eur Rev Med Pharmacol Sci 2013;17:1655-7.
30. Leung AKC, Lai PCW. Use of metoclopramide for the treatment of gastroesophageal reflux in infants and children. Curr Ther Res Clin Exp 1984;36:911-5.
31. Bellissant E, Duhamel JF, Guillot M, et al. The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux. Clin Pharmacol Ther 1997;61:377-84.
32. Lightdale JR, Gremse DA. Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics 2013;131:1684-95.
33. Vandenplas Y, Rudolph CD, Di Lorenzo, C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009;49:498-547.
34. Vandenplas Y. Management of paediatric GERD. Nat Rev Gastroenterol Hepatol 2014;11:147-57.
35. Clark RH, Spitzer AR. Patience is a virtue in the management of gastroesophageal reflux. J Pediatr 2009;155:464-5.
36. Dubin A, Kikkert M, Mirmiran M, et al. Cisapride associated with QTc prolongation in very low birth weight preterm infants. Pediatrics 2001;107:1313-6.
37. Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-703.
38. Shaffer D, Butterfield M, Pamer C, et al. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc 2004;44:661-5.
39. Ellsbury DL, Ursprung R. A quality improvement approach to optimizing medication use in the neonatal intensive care unit. Clin Perinatol 2012;39:1-10.
40. Stein MH, Sorscher M, Caroff SN. Neuroleptic malignant syndrome induced by metoclopramide in an infant with Freeman-Sheldon syndrome. Anesth Analg 2006;103:786-7.
41. Malcolm WF, Gantz M, Martin RJ, et al. Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants. Pediatrics 2008;121:22-7.